|
1
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar
|
|
2
|
Oser MG, Niederst MJ, Sequist LV and
Engelman JA: Transformation from non-small-cell lung cancer to
small-cell lung cancer: Molecular drivers and cells of origin.
Lancet Oncol. 16:e165–e172. 2015. View Article : Google Scholar :
|
|
3
|
Mascaux C, Tomasini P, Greillier L and
Barlesi F: Personalised medicine for nonsmall cell lung cancer. Eur
Respir Rev. 26:1700662017. View Article : Google Scholar
|
|
4
|
Lin Y, Wang X and Jin H: EGFR-TKI
resistance in NSCLC patients: Mechanisms and strategies. Am J
Cancer Res. 4:411–435. 2014.
|
|
5
|
Green DR and Chipuk JE: p53 and
metabolism: Inside the TIGAR. Cell. 126:30–32. 2006. View Article : Google Scholar
|
|
6
|
Mogi A and Kuwano H: TP53 mutations in
nonsmall cell lung cancer. J Biomed Biotechnol. 2011:5839292011.
View Article : Google Scholar :
|
|
7
|
Brosh R and Rotter V: When mutants gain
new powers: News from the mutant p53 field. Nat Rev Cancer.
9:701–713. 2009. View
Article : Google Scholar
|
|
8
|
Steels E, Paesmans M, Berghmans T, Branle
F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ and
Sculier JP: Role of p53 as a prognostic factor for survival in lung
cancer: A systematic review of the literature with a meta-analysis.
Eur Respir J. 18:705–719. 2001. View Article : Google Scholar
|
|
9
|
Yue X, Zhao Y, Xu Y, Zheng M, Feng Z and
Hu W: Mutant p53 in cancer: Accumulation, gain-of-function and
therapy. J Mol Bio. 429:1595–1606. 2017. View Article : Google Scholar
|
|
10
|
Demma M, Maxwell E, Ramos R, Liang L, Li
C, Hesk D, Rossman R, Mallams A, Doll R, Liu M, et al: SCH529074, a
small molecule activator of mutant p53, which binds p53 DNA binding
domain (DBD), restores growth-suppressive function to mutant p53
and interrupts HDM2-mediated ubiquitination of wild type p53. J Bio
Chem. 285:10198–10212. 2010. View Article : Google Scholar
|
|
11
|
Parrales A and Iwakuma T: Targeting
oncogenic mutant p53 for cancer therapy. Front Oncol. 5:2882015.
View Article : Google Scholar :
|
|
12
|
Cui T, Chen Y, Yang L, Knösel T, Zöller K,
Huber O and Petersen I: DSC3 expression is regulated by p53, and
methylation of DSC3 DNA is a prognostic marker in human colorectal
cancer. Br J Cancer. 15:1013–1019. 2011. View Article : Google Scholar
|
|
13
|
Li Y, Chen Y, Ma Y, Nenkov M, Haase D and
Petersen I: Collagen prolyl hydroxylase 3 has a tumor suppressive
activity in human lung cancer. Exp Cell Res. 363:121–128. 2018.
View Article : Google Scholar
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar
|
|
16
|
Weinberg RA: p53 and apoptosis: Master
guardian and executioner. The Biology of Cancer. Garland Science,
Taylor & Francis Group; New York, NY: pp. 331–389. 2014
|
|
17
|
Levine B and Abrams J: p53: The Janus of
autophagy? Nat Cell Biol. 10:637–639. 2008. View Article : Google Scholar :
|
|
18
|
Tanida I, Ueno T and Kominami E: LC3 and
autophagy. Methods Mol Biol. 445:77–88. 2008. View Article : Google Scholar
|
|
19
|
Zhou X, Hai Q and Lu H: Mutant p53 in
cancer therapy-the barrier or the path. J Mol Cell Biol.
11:293–305. 2019. View Article : Google Scholar
|
|
20
|
Lee YS, Yoon S, Park MS, Kim JH, Lee JH
and Sonog CW: Influence of p53 expression on sensitivity of cancer
cells to bleomycin. J Biochem Mol Toxicol. 24:260–269. 2010.
View Article : Google Scholar
|
|
21
|
Bykov VJ, Issaeva N, Shilov A, Hultcrantz
M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G:
Restoration of the tumor suppressor function to mutant p53 by a
low-molecular-weight compound. Nat Med. 8:282–288. 2002. View Article : Google Scholar
|
|
22
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar :
|
|
23
|
Karimian A, Ahmadi Y and Yousefi B:
Multiple functions of p21 in cell cycle, apoptosis and
transcriptional regulation after DNA damage. DNA Repair (Amst).
42:63–71. 2016. View Article : Google Scholar
|
|
24
|
Jeong JH, Kang SS, Park KK, Chang HW,
Magae J and Chang YC: p53-independent induction of G1 arrest and
p21WAF1/CIP1 expression by ascofuranone, an isoprenoid antibiotic,
through downregulation of c-Myc. Mol Cancer Ther. 9:2102–2113.
2010. View Article : Google Scholar
|
|
25
|
Arachchige Don AS, Dallapiazza RF, Bennin
DA, Brake T, Cowan CE and Horne MC: Cyclin G2 is a
centrosome-associated nucleocytoplasmic shuttling protein that
influences microtubule stability and induces a p53-dependent. Exp
Cell Res. 312:4181–4204. 2006. View Article : Google Scholar :
|
|
26
|
Sun GG, Zhang J and Hu WN: CCNG2
expression is down-regulated in colorectal carcinoma and its
clinical significance. Tumour Biol. 35:3339–3346. 2014. View Article : Google Scholar
|
|
27
|
Strasser A, Harris AW, Jacks T and Cory S:
DNA damage can induce apoptosis in proliferating lymphoid cells via
p53-independent mechanisms inhibitable by Bcl-2. Cell. 79:329–339.
1994. View Article : Google Scholar
|
|
28
|
Montero J and Letai A: Why do BCL-2
inhibitors work and where should we use them in the clinic? Cell
Death Differ. 25:56–64. 2018. View Article : Google Scholar
|
|
29
|
Yu J and Zhang L: PUMA, a potent killer
with or without p53. Oncogene. 27 (Suppl 1):S71–S83. 2008.
View Article : Google Scholar :
|
|
30
|
Wu B, Qiu W, Wang P, Yu H, Cheng T,
Zambetti GP, Zhang L and Yu J: p53 independent induction of PUMA
mediates intestinal apoptosis in response to ischaemia-reperfusion.
Gut. 56:645–654. 2007. View Article : Google Scholar
|
|
31
|
Ambroise G, Portier A, Roders N, Arnoult D
and Vazquez A: Subcellular localization of PUMA regulates its
pro-apoptotic activity in Burkitt's lymphoma B cells. Oncotarget.
6:3818–3894. 2015. View Article : Google Scholar
|
|
32
|
Zheng X, He K, Zhang L and Yu J:
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
Mol Cancer Ther. 12:777–786. 2013. View Article : Google Scholar :
|
|
33
|
Hafner A, Bulyk ML, Jambhekar A and Lahav
G: The multiple mechanisms that regulate p53 activity and cell
fate. Nat Rev Mol Cell Biol. 20:199–210. 2019. View Article : Google Scholar
|
|
34
|
Smith MA, Gorlick R, Kolb EA, Lock R,
Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, et al:
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric
preclinical testing program. Pediatr Blood Cancer. 59:329–332.
2012. View Article : Google Scholar
|
|
35
|
Cordani M, Butera G, Pacchiana R and
Donadelli M: Molecular interplay between mutant p53 proteins and
autophagy in cancer cells. Biochim Biophys Acta Rev Cancer.
1867:19–28. 2017. View Article : Google Scholar
|
|
36
|
Mizushima N and Yoshimori T: How to
interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007.
View Article : Google Scholar
|
|
37
|
Huang S and Sinicrope FA:
Celecoxib-induced apoptosis is enhanced by ABT-737 and by
inhibition of autophagy in human colorectal cancer cells.
Autophagy. 6:256–269. 2010. View Article : Google Scholar :
|
|
38
|
Matlock K, Berlow N, Keller C and Pal R:
Combination therapy design for maximizing sensitivity and
minimizing toxicity. BMC Bioinformatics. 18 (Suppl 4):S1162017.
View Article : Google Scholar
|
